Response to Anti-HER2-Based Treatment in a Patient with Bladder Adenocarcinoma Harboring HER2 Amplification and S310F Mutation Discovered by Next-Generation Sequencing: A Case Report.
Xiaolu WangWenjing HuLi XiePublished in: OncoTargets and therapy (2020)
This is the first case report describing a bladder adenocarcinoma patient harboring HER2 amplification who responded to trastuzumab. NGS is of great potential in the selection of bladder adenocarcinoma patients suitable for anti-HER2 therapy. The genetic change after treatment also implied possible mechanisms of resistance to trastuzumab-based therapy, which requires more investigation.
Keyphrases
- case report
- spinal cord injury
- squamous cell carcinoma
- end stage renal disease
- locally advanced
- epidermal growth factor receptor
- ejection fraction
- newly diagnosed
- chronic kidney disease
- nucleic acid
- copy number
- peritoneal dialysis
- urinary tract
- prognostic factors
- metastatic breast cancer
- radiation therapy
- gene expression
- dna methylation
- risk assessment
- patient reported outcomes
- tyrosine kinase
- human health